COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF.

Dear Sirs,

Although the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is known to induce encephalopathy [1, 2] this condition has not yet been well characterized. Furthermore, a reliable cerebrospinal fluid (CSF) biomarker for coronavirus disease 2019 (COVID-19) is currently lacking. Here, we report on the novel clinical and imaging characteristics of two cases of COVID-19 encephalopathy. Notably, we detected anti-SARS-CoV-2 antibodies in the patients’ CSF samples.

A middle-aged woman with an unremarkable medical history developed exertional dyspnea after 7 days of fever and anosmia. A CT scan of the thorax showed bilateral interstitial pneumonia, and a nasopharyngeal swab was positive for SARS CoV-2 in a reverse-transcriptase polymerase chain reaction (RT-PCR) assay. Although the woman had fully recovered from pneumonia by day 11 in the absence of treatment, she progressively developed (from day 16 onwards) gait disturbance and was admitted to our neurology department. A neurological examination showed a slight motor impairment of the lower limbs, pyramidal signs, hypopallesthesia of the four limbs, and bladder and bowel incontinence. Motor and sensory evoked potentials were impaired, indicating supraspinal impairment. Magnetic resonance imaging (MRI) of the spine was normal. Non-contrast-enhanced brain MRI revealed medial mesencephalic hyperintensity with a normal apparent diffusion coefficient (ADC) (Supplementary Figure A). The electroencephalogram and electroneuromyogram were normal.

A middle-aged man with a history of type 2 diabetes, hypertension and dyslipidemia developed severe acute respiratory syndrome in the context of asthenia and fever with bilateral interstitial pneumonia on a CT scan of the thorax. A nasal sample was positive for SARS-CoV-2 in an RT-PCR assay. The man was admitted to the intensive care unit and intubated 3 days later for acute respiratory distress syndrome. Despite the withdrawal of sedation, the patient did not awaken (Glasgow score: 6; eyes: 3; verbal: 1; motor: 2); the pupillary response was maintained, and flaccid tetraparalysis was observed. Brain MRI showed bilateral diffuse white matter hyperintensities with a normal ADC. Gadolinium contrast enhancement revealed intense hemorrhagic lesions in both pallidi, with a low ADC (Supplementary Figure B).

In both cases, exhaustive clinical and laboratory assessments failed to identify an alternative diagnosis for the encephalopathy (e.g., a toxic, metabolic, inflammatory, or infectious cause). The two patients’ CSF samples had an elevated protein level, normal cytology results, an elevated glucose level, normal Delpech indices, no intrathecal synthesis of immunoglobulin was observed at isoelectrofocusing (IEF). A “mirrored profile” was detected on each patient's IEF, suggesting an increased permeability of the hemato-encephalic barrier. Furthermore, the samples tested negative in standard bacterial cultures, a meningitis/encephalitis multiplex virus PCR assay, and a specific SARS-CoV-2 PCR assay (Supplementary Table).

To detect SARS-Cov2 antibodies, the two patients’ CSF samples were tested for the presence of SARS-CoV-2 spike 1, spike 2 and nucleoprotein antigens, using ELISAs (The Native Antigen Company, Kidlington, UK; for details of the method, see the Supplementary Appendix). This analysis was approved by institutional review board at Amiens University Hospital (reference: PI2020_843_0048, dated April 24th, 2020). The CSF samples from both patients were strongly positive for the viral nucleoprotein. The signals were weaker for the SARS-CoV-2 spike antigens but still exceeded the assay’s threshold. For each viral antigen, reactivity was greater for patient 2’s samples (Fig. 1). The transudation percentages were 1.08 and 3.12% for patients 1 and 2, indicating that the presence of these antibodies in the CSF was due to transudation.

Fig. 1

The contents of CSF samples from COVID-19 patients were allowed to bind to immobilized SARS-CoV-2 S1 protein, S2 protein, and nucleoprotein. To calculate the cutoff, CSF samples collected from other patients in June 2019 were used as negative controls. The cutoff was calculated as the mean plus three standard deviations, and is represented by the dashed horizontal line

The present results illustrate the variety of clinical and imaging characteristics of COVID-19 encephalopathy and, most interestingly, indicate that antibodies against SARS-CoV-2 can be found in the CSF. Although the specificity of this feature remains to be established, it may constitute a critical diagnostic marker.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 17 kb)

Supplementary file2 (DOCX 2775 kb)